ライフサイエンスコーパス: payload

1 must experience before it releases it's drug payload.

2 other ADCs with maytansinoid derivatives as payload.

3 sma, exactly matching the mass of the linker-payload.

4 capable of carrying a nucleic acid analogue payload.

5 roperties make MSCs ideal carriers for toxic payload.

6 tion, and effective intracellular release of payload.

7 crease the therapeutic index of the cytokine payload.

8 ulting in subsequent endocytic uptake of the payload.

9 spontaneous swelling and fast releasing its payload.

10 geneity, release or skin distribution of the payload.

11 te platelets to secrete their pro-angiogenic payload.

12 cles in specifically delivering an antitumor payload.

13 ciation of Tf within the cell to deliver its payload.

14 sa, while retaining the effectiveness of the payload.

15 nhaled particles delivered their therapeutic payload.

16 increasing the number of cells that received payload.

17 armed with a monomethyl auristatin E (MMAE) payload.

18 y and monomethyl auristatin E as a cytotoxic payload.

19 able linker, and a topoisomerase I inhibitor payload.

20 drugs and the NIR light triggered release of payloads.

21 niumdiolate NO donors and greater NO-release payloads.

22 omes during internalization of extracellular payloads.

23 can easily be loaded with a diverse range of payloads.

24 ers for systemic delivery of a wide array of payloads.

25 ects while specifically delivering cytotoxic payloads.

26 esulting in targeted delivery of therapeutic payloads.

27 ing the controlled release of pharmaceutical payloads.

28 controlled release of therapeutic monolayer payloads.

29 ivo delivery of PEMs containing biomolecular payloads.

30 ention as potential carriers for therapeutic payloads.

31 all tumor regions and delivering therapeutic payloads.

32 h for noninvasive dosimetry of targeted drug payloads.

33 an the level of drug required with other ADC payloads.

34 s prominently includes their protein and RNA payloads.

35 ow site-specific conjugation with various Ag payloads.

36 antibodies armed with potent small-molecule payloads.

37 of widely varying sizes (d = 20-500 nm), NO payloads (50-1780 nmol.mg-1), maximum amounts of NO rele

38 ne liver fibrosis model enhanced carrier and payload accumulation in the fibrotic tissue facilitated

39 nd interactions, and transport and release a payload across an inflamed reconstructed endothelium.

40 le of in vivo formation of an albumin-linker-payload adduct.

41 albumin, forming a long-lived albumin-linker-payload adduct.

42 The inhibitors comprise PAYLOAD and COMBI stages, which interact with active sit

43 c acid take too long to release encapsulated payload and fail to induce high levels of target gene ex

44 anoparticles (LPSiNPs) that can carry a drug payload and of which the intrinsic near-infrared photolu

45 The nanorattles enable targeted delivery of payload and simultaneous monitoring of the payload relea

46 imultaneous imaging of TNP vehicle, its drug payload and single-cell DNA damage response reveals that

47 a tumor-specific antibody able to deliver a payload and unveils the target antigen.

48 trongly on the variability and skew of truck payloads and bus ridership.

49 methane leakage rate, to achieving the same payloads and cargo volumes as conventional diesel trucks

50 orts are directed to identify more effective payloads and simplify current manufacturing challenges.

51 DNA, because such particles protect plasmid payloads and target them to phagocytic antigen-presentin

52 he notion that SNAs can serve as therapeutic payloads and targeting structures to engage biological p

53 dy, linker, conjugation site, small-molecule payload, and drug-to-antibody ratio (DAR).

54 ective delivery and release of water-soluble payloads, and can be coupled to enzyme activity within t

55 ing better targets, more effective cytotoxic payloads, and further improvements in antibody-drug link

56 orable pharmacokinetics for some therapeutic payloads, and that they are targeted against only a sing

57 When coupled to antigenic payloads, anti-MHCII VHH primed Ab responses against GFP

58 As aptamers can be modified to deliver payloads, aptamers may represent novel agents that could

59 ow that intact mitochondria with their mtDNA payload are transferred in the developing tumour, and pr

60 iophysical properties and amount of released payloads are chief factors determining the overall ADC p

61 Charged peptide payloads are loaded into the pores of the pSiNP at appro

62 antibodies to focus the activities of toxic payloads at tumor sites are under way and show early pro

63 mparting a bulking effect to the therapeutic payloads attached to them.

64 he range of 2.5 to 2.7 and approximately 85% payload bound to the Fc region, presumably to histidine

65 l nanoparticle-drug conjugate containing the payload camptothecin (CPT), to improve therapeutic respo

66 dence of either the nanoparticle or its drug payload (camptothecin, CPT) contained within the nanopar

67 e as multifunctional carrier systems because payload can be encapsulated in internal space whilst out

68 eedle-generated pores, from which the active payload can be released and diffuse laterally into the n

69 livery vehicles, from which the release of a payload can be triggered by NIR light and the release ra

70 Therapeutic payloads can be targeted selectively to eosinophils and

71 ed nanoparticle (NP) encapsulating a CDDO-Im payload capable of specific delivery to the TME, which s

72 y platforms due to the ability to tune their payload capacities and release rates by adjusting the lo

73 for monogenic diseases; however, the limited payload capacity of AAVs combined with the large number

74 n greater transgene expression by increasing payload capacity with prior DNA incubation without compr

75 NA NPs, which are non-toxic and have a large payload capacity, expand the treatment repertoire availa

76 of its potential immunogenicity and limited payload capacity.

77 NP(BTZ-DOX) prolonged payload circulation and targeted tumors in vivo efficien

78 The precision additives reach high payloads close to 1:1, rendering a photosensitizer water

79 on the release profile of particular carrier/payload combinations.

80 observed between the measured released free payload concentration and the measured loss of drug-to-a

81 s using these chemistries yielding efficient payload conjugation.

82 Over 85,000 m3 of waste in various vented payload containers have been emplaced in the repository.

83 ssues, we hypothesized that blood-borne drug payloads could be modified to home to and refill hydroge

84 ve DAR was lowered, decreasing the amount of payload delivered to each targeted cell but increasing t

85 the "double-layered particle" (DLP), is the "payload" delivered into a cell in the process of viral i

86 nables targeting specificity and therapeutic payload delivery to treat a variety of surgical diseases

87 ally-actuated peptides for tumor-penetrative payload delivery.

88 utics with an emphasis on site-specific drug payload delivery.

89 ed enhanced cytotoxic activity from targeted payload delivery.

90 ivation, and reconfiguring its structure for payload delivery.

91 rget radiation dose to healthy tissue during payload delivery.

92 preferentially bind to pancreatic tumors for payload delivery.

93 y to guarantee the protection and controlled payload delivery.

94 ies were found to be antibody-, linker-, and payload-dependent.

95 sents developments in vector engineering and payload design aimed at tailoring AAV vectors for transd

96 As a consequence, the proteinosome payload (dextran, single-stranded DNA, platinum nanopart

97 The mechanism and kinetics of the payload discharge appeared to be phospholipase A2 activi

98 fective for 3 reasons: (1) it was small; (2) payload dispersal mechanisms were inefficient; and (3) c

99 ise dose whilst ensuring that the dry-coated payload does not significantly impact on MN skin penetra

100 atumoral distribution of ADC, independent of payload dose or plasma clearance, plays a major role in

101 and enhance the anticancer potency of a drug payload (doxorubicin hydrochloride).

102 e Tf has a low probability of delivering its payload due to its short residence time in the cell, or

103 shed in order to separate the effects of the payload during degradation.

104 to achieve the controlled release of a model payload (e.g., silica nanoparticles) encapsulated within

105 carriers for the delivery of macromolecular payloads, e.g. nucleic acids.

106 poration have also been developed to achieve payload encapsulation.

107 However, compared to (111)In-labeled payload EPI, (125)I-labeled EPI showed lower radioactivi

108 hancing the efficacy of their macromolecular payload, especially the payloads that are susceptible to

109 phoethanolamine (DSPE) released up to 30% of payload following ultrasound exposure in the presence of

110 ic acid component acts as both a therapeutic payload for intracellular gene regulation and the delive

111 They may also serve as an active payload for self-healing hydrogels or repair of biologic

112 ed into a nanostructure carrying a high drug payload for specific drug delivery.

113 nes both biological barriers and nanocarrier payloads for a variety of drug delivery applications.

114 of PBDs, and the strategies for their use as payloads for ADCs.

115 ted picomolar potencies that qualify them as payloads for antibody drug conjugates (ADCs), while a nu

116 ogues of these natural products as potential payloads for antibody-drug conjugates and other delivery

117 overed in this study are highly desirable as payloads for antibody-drug conjugates and other drug del

118 ferent selectivities and biologically active payloads for cell-targeting tasks.

119 volumes, and in encapsulation and release of payloads for site-directed drug delivery.

120 s and others like them may serve as powerful payloads for the development of antibody drug conjugates

121 We found that an enzymatic release of payload from ADC-depleted human plasma at 144 h was able

122 lised to both trigger and monitor release of payload from liposomes.

123 -triggered drug release while preventing the payloads from lysosomal degradation.

124 confocal microscopy showed a dissociation of payloads from the early endosome indicating translocatio

125 gnificant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells.

126 y-drug conjugates (ADCs) containing multiple payloads has been developed.

127 loration Rover Spirit and its Athena science payload have been used to investigate a landing site in

128 Nanoparticles and their payloads have also been favorably delivered into tumors

129 que nanomedicine demonstrates: (i) high drug payload, (ii) decreased toxicity of the coupled anticanc

130 asma stability coupled with rapid release of payload in a lysosomal environment.

131 o block copolymers that secure a therapeutic payload in an inactive state.

132 Nucleic acids are generally regarded as the payload in gene therapy, often requiring a carrier for i

133 PE3 is widely used as a cytocidal payload in receptor-targeted protein toxin conjugates.

134 whereas liposomes designed to release their payload in the acidic environments show a loss of integr

135 ecombination and excision of its therapeutic payload in the presence of the Flp and Sleeping Beauty r

136 their ability to store and deliver larger NO payloads in a more controlled and effective manner compa

137 acokinetics and biodistributions of the drug payloads in animal models.

138 ubule inhibitors that are clinically used as payloads in antibody-drug conjugates (ADCs).

139 the United States: exchanging genomics data payloads in excess of 500GiB using the uTorrent client s

140 livery of both plasmid DNA and messenger RNA payloads in stem cells, primary cells, and human cell li

141 otides (ODNs) that provide a target for drug payloads in the form of free alginate strands carrying c

142 rrolobenzodiazepine dimer (PBD) or tubulysin payloads induce ICD, modulate the immune microenvironmen

143 he release of encapsulated doxorubicin (DXR) payload inside the liposomal core under mild acidic cond

144 l buffers and only release their therapeutic payload into cancer cells after a time-dependent cellula

145 the proposed NLCS effectively delivered its payload into lung cancer cells leaving healthy lung tiss

146 at low pH and enable release of the liposome payload into the cytoplasm.

147 em featuring stimuli-responsive release of a payload into the cytosol with fluorescence monitoring.

148 low for the efficient release of their siRNA payload into the cytosol.

149 ptide along with attached or co-administered payload into the tumor mass.

150 tivated mechanisms the endoscope can deliver payloads into cells with spatial and temporal specificit

151 s capable of specifically delivering genetic payloads into the human genome.

152 specific cell targeting and the delivery of payloads into the target cell.

153 y an integrin-mediated process, releases its payload intracellularly, and is a highly potent inhibito

154 technique to refill these systems once their payload is exhausted.

155 ost cell via endocytosis, at which point the payload is triggered to be released into the cytoplasm.

156 F) while maintaining the activity of protein payloads is reported.

157 Evaluation of cargo incorporation and payload levels in vitro and in vivo can be assessed via

158 ), respectively, after i.v. injection of the payload loaded HA NPs in tumor bearing mice.

159 h sperm during epididymal transit) carry RNA payloads matching those of mature sperm and can deliver

160 In contrast, a less membrane permeable payload, MMAF, failed to mediate bystander killing in vi

161 line L-82, but delivered the same cytotoxic payload (monomethyl auristatin E, MMAE), and we found th

162 Animals immunized with a high-payload monovalent FMD vaccine developed high titers of

163 t delivery kinetics as measured by different payloads: nanoparticle encapsulated DiR was observed to

164 an encapsulation efficiency of 99.82% and a payload of 52.56%.

165 s concomitant with controlled release of the payload of anti-inflammatory drug.

166 to a water-soluble Rh(I) complex carrying a payload of compound with unsaturated (C horizontal lineC

167 Concentrating a high payload of divalent copper ions per nanoparticle, this a

168 latform to facilitate the delivery of a high payload of imaging reporters or targeting moieties witho

169 breviated as P-SMART), with 14.3+/-2.8% drug payload of SMART-OH.

170 ast-enhanced MRI (DCE-MRI) and the resulting payload of the chemotherapy agent, doxorubicin (DOX).

171 that the microparticle will deliver a large payload of virus to cells and serve to protect the AAV f

172 These NCP particles contain high payloads of chemotherapeutics cisplatin or cisplatin plu

173 it is demonstrated that the DNF can deliver payloads of cytotoxic protein (i.e., RNase A) to the cel

174 NMR spectrometer for efficient production of payloads of hyperpolarized contrast agent and in situ qu

175 at allow VNP/VLP formulations to carry large payloads of imaging reagents or drugs.

176 und to be LpDNA dose-dependent, where higher payloads of pDNA resulted in a higher transfection rate.

177 5.6 micromol NO/mg), greatly increasing the "payload" of released NO over existing macromolecular NO

178 ein subunits (Cmr1-7) and carries a diverse "payload" of targeting crRNA.

179 tputs, which are relayed to switch molecular payloads on or off.

180 We show that these payloads on their own induced an immune response that pr

181 livery platform that releases its antibiotic payload only at the site of infection and only in the pr

182 xygen gas and that they release their oxygen payload only when exposed to desaturated blood.

183 roduction of oligoglycine-modified cytotoxic payloads or NIR fluorophores.

184 dentity test is performed in which the viral payload, or transgene, is PCR amplified, followed by dig

185 , which incorporate new types of linkers and payloads other than maytansines and auristatins, are mor

186 Sutures released their entire drug payload over the course of 12 days and maintained approx

187 They have been conjugated to toxic payloads, PEGs, or radioisotopes to increase and optimiz

188 that 173 +/- 38 polymersomes released their payload per cell, with significant heterogeneity in upta

189 epended on the size, shape and number of the payload per nanoparticles.

190 s and can be loaded with RNA as an antigenic payload, permitting simultaneous targeting of multiple a

191 Thus, F3 can carry a payload (phage, fluorescein) to a tumor and into the cel

192 For example, the payload portion of XJB-5-131 consists of a stable nitrox

193 ortunity to image the dispersion of the drug payload post release.

194 number of potent, tumor-specific therapeutic payloads potentially available for delivery.

195 A DNA payload, pre-compressed by protamine, was encapsulated i

196 PHIP-available complexes with an unsaturated payload precursor molecule can be extended to other cont

197 oride), as well as 140 copies of therapeutic payload proflavine (PF, acridine-3,6-diamine hydrochlori

198 sive libraries of toxins and other predicted payload proteins.

199 able targeting and incorporate a therapeutic payload, provides a new and innovative therapeutic platf

200 er for shielding of core materials and their payloads, providing for prolonged circulation in vivo by

201 ylethanolamine (Q-DOPE) lipids, and complete payload release (quenched fluorescent dye) from Q-DOPE l

202 f payload and simultaneous monitoring of the payload release and the therapy process.

203 eneous delivery after 1 day, degradation and payload release by 2 days, and in vitro cell killing and

204 Payload release by aggregation and leakage of "uncapped"

205 search is endogenous triggering of liposomal payload release by overexpressed enzyme activity in affe

206 Movement and payload release from these plasmon resonant nanocapsules

207 s study, we investigated the degree to which payload release predicts ADC activity in vitro and in vi

208 eloped cPPA programmable microcapsules whose payload release rates depend on the composition and conc

209 Mass spectrometry studies of payload release suggested that other cysteine cathepsins

210 Controllable payload release through judicious design of the linker h

211 o trigger a 16-fold increase in the level of payload release within tumors following intravenous deli

212 , leading to increase of cellular uptake and payload release, and inhibition of cell proliferation by

213 ize of the silicon particles to regulate the payload release.

214 ar attention to the location and dynamics of payload release.

215 local diffusion and distribution of released payloads represents a potential mechanism of ADC-mediate

216 yl-glutaryl-CoA reductase siRNA as an active payload resulting in a reduction of plasma cholesterol l

217 ous because it allows for the development of payloads separately from the binding/translocation compo

218 When coupled to a drug payload, sequence-targeted refilling of a delivery depot

219 ecause of the vital importance of minimising payload (size and mass).

220 llisional cross sections measurement of each payload species attesting slight conformational changes.

221 Lastly, inhibition data confirm the PAYLOAD stage directs the inhibitors to the ADCS active

222 zation-degradation pathway to deliver active payloads, strategies aimed at restoring lysosomal functi

223 defined capacity for additional biotinylated payloads such as other antibodies to create bispecific a

224 geted delivery of diagnostic and therapeutic payloads such as radionuclides and drugs into neoplastic

225 lti-specific reagents, linked to therapeutic payloads (such as radionuclides, toxins, enzymes, liposo

226 and local delivery of non-native therapeutic payloads, such as antibodies, in response to antigen.

227 nal carriers designed for different types of payloads, surveying the biomaterials used to construct t

228 avior allows the receptor to carry a greater payload than would be possible in a noncooperative analo

229 vectors are also able to carry more complex payloads than murine retroviral vectors, making it possi

230 odates a wide range of natural and synthetic payloads that allow modification of RBCs with substituen

231 their macromolecular payload, especially the payloads that are susceptible to lysosomal degradation.

232 e find that CDI nuclease domains are modular payloads that can be redirected through different import

233 r multiplexing targeting ligands and/or drug payloads that can be selected after base nanocarrier for

234 main peptides (MDP) can be tailored to carry payloads that modulate the extracellular environment.

235 device strategies load CGM sensors with drug payloads that release locally to tissue sites to mitigat

236 ion of nitric oxide (NO) as a function of NO payload, the validity of such work is often questionable

237 rm to deliver surface-loaded and core-loaded payloads, the particles were labeled either with the opt

238 One approach consists of coupling a payload--the portion of the molecule with ROS-scavenging

239 od circulation between polymeric carrier and payload; the carriers ((111)In-2P and (125)I-2P) showed

240 gene target and a drug target using only the payloads themselves, bypassing the need for a cocarrier

241 Prefabricated Ads with different payloads thus can be retargeted readily to many cell typ

242 Based on these observations, we altered the payload to a pyrrolo[2,1-c][1,4]benzodiazepine dimer (PB

243 is technology enables in vitro delivery of a payload to a selected cell and may be applied to the int

244 ii) a novel tandem peptide cargo to localize payload to bacterial membranes.

245 y and preferentially deliver its therapeutic payload to both primary and metastatic tumors.

246 r mimic extracellular matrix or to deliver a payload to diseased tissue.

247 din segment was used to target the nitroxide payload to mitochondria because antibiotics of this type

248 ug development are made by coupling a linker-payload to native or engineered cysteine residues on the

249 cules with ideal properties for delivering a payload to target cells.

250 ted bacteria delivering a highly radioactive payload to the metastases, resulting in killing tumor ce

251 oming peptide that specifically delivers its payload to the mitochondria of tumor endothelial cells a

252 capacity to efficiently deliver a transgene payload to the target cells in a receptor-specific manne

253 nly delivers a cytotoxic or an immunotherapy payload to the tumor but also reports back on the effica

254 hat exert a functional activity or deliver a payload to the tumor site.

255 ith direct paracrine delivery of a bioactive payload to transplanted ovarian tissue.

256 les the targeted delivery of its therapeutic payload to tumors based on cell-surface receptor recogni

257 gy for the conjugation of alcohol-containing payloads to antibodies has been developed and involves t

258 sed for coupling maleimide-containing linker-payloads to antibodies resulting in the generation of an

259 A challenge in tumor targeting is to deliver payloads to cancers while sparing normal tissues.

260 nanorobot capable of transporting molecular payloads to cells, sensing cell surface inputs for condi

261 the selective pharmacodelivery of cytotoxic payloads to diseased tissues, providing an innovative pl

262 es must be able to deliver their therapeutic payloads to metastatic lesions after systemic administra

263 in was used to deliver fluorescently labeled payloads to Neuro-2a cells.

264 ugation method to enable precise addition of payloads to proteins, synthesis of antibody-drug conjuga

265 ry of nanoscale carriers containing packaged payloads to the central nervous system has potential use

266 cific cell types, delivering their enzymatic payloads to the cytosol.

267 s, and targeting polymers/nanoparticles with payloads to the mitochondria.

268 micelles are able to deliver contrast agent payloads to tumors expressing the MC1R.

269 highly potent killing activity of drugs with payloads too toxic for systemic administration.

270 Unfortunately, limited NO payloads, too rapid NO release, and the lack of targeted

271 tatively characterizing the extent of linker-payload transfer to serum albumin and the first clear ex

272 can rapidly and effectively release its DOX payload triggered by an acidic pH environment (pH~5) and

273 The peptides were able to take payloads up to the nanoparticle size scale deep into ext

274 ds to autonomous release of the encapsulated payload upon gastric-acid neutralization by the motors.

275 via the antibody and release their cytotoxic payload upon internalization.

276 Triggered burst release of the payload upon irradiation and subsequent degradation of t

277 oxic conjugate that effectively releases the payload upon long wavelength UV irradiation.

278 on two different routes with three different payloads using a portable emissions measurement system (

279 The highest payload was 0.56(+/-0.01) mumol SNAP/mg microspheres.

280 The payload was conjugated to trastuzumab by a protease-clea

281 jugated via hinge-cysteines to an auristatin payload was used as a model in this study to understand

282 release, the release of Nile Red as a "model payload" was examined.

283 t brain delivery for multiple small molecule payloads, we observed minimal evidence for targeting to

284 gnatures characteristic of both particle and payload when exposed to lowered pH conditions, demonstra

285 re able to efficiently deliver intracellular payloads when attached to nanoparticles such as liposome

286 m silicate shell traps and protects an siRNA payload, which can be delivered to neuronal tissues in v

287 the attachment of other functional units or payloads while retaining low-micromolar or better affini

288 eared, the erythrocyte surface-bound antigen payload will be cleared tolerogenically along with the e

289 The hydrogels released 50% of their payload within 30min and enhanced the accumulation of GA

290 subsequent entrapment and degradation of the payload within acidic/digestive lysosomal compartments.

291 nanocarriers released ~75% of the paclitaxel payload within six hours in acidic pH, which was accompa

292 cells for several days and release their RA payloads within a few minutes upon exposure to blue/UV l

293 self-immolative unit for alcohol-containing payloads within ADCs, a class that has not been widely e

294 uccessfully deliver relatively high antibody payloads within different types of live cells.

295 to induce the targeted release of liposomal payloads within tumors.

296 lize gastric acid and simultaneously release payload without causing noticeable acute toxicity or aff

297 nker that enables postformulation editing of payloads without the need for reformulation to achieve m

298 roles in imaging by delivering large imaging payloads, yielding improved sensitivity, multiplexing ca